Pearl Street Venture Funds
VC Fund
Indianapolis, United States
Pearl Street Venture Funds is an Indiana-based venture capital fund investing in innovative life sciences companies to provide superior financial returns for its limited partners.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Pearl Street Venture Funds invests in
Stages Pearl Street Venture Funds invests in
Countries Pearl Street Venture Funds invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Tim Tichenor
|
|||
Investment Focus
Industry
- Biotechnology 3 (43%)
- Medical 1 (14%)
- Robotics 1 (14%)
- Health Care 1 (14%)
- Real Estate 1 (14%)
Stage
- Series A 2 (29%)
- Pre-Seed 1 (14%)
- Series B 1 (14%)
- Series C 1 (14%)
- Series D 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Tim Tichenor
Managing Director
|
Managing Director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Toggle
|
How will we build the next generation of cities and infrastructure when key construction methods have remained unchanged for a generation? As the built environment grows larger and more complex Toggle is introducing industrial robotics and automation to critical construction methods and materials. Starting with rebar for reinforced concrete Toggleis reinventing the way we build our world. | $570K / Pre-Seed / Nov 10, 2018 | |
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $37.1M / Series C / Jan 13, 2015 | |
|
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $7.5M / Aug 30, 2011 | |
|
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $25M / Series B / Jul 01, 2008 | |
Serenex
|
Serenex is a medical drug discovery and development company that focuses on oncology. The company develops Hsp90 product platform that provides a collection of small molecule Hsp90 inhibitors for cancer, inflammatory diseases, fungal infection resistance, viral diseases, and neurodegenerative diseases, such as Alzheimer's. It also developsSNX-1012, a product for oral mucositis in solid tumor patients.Serenex is a U.S.-based company that was founded in 2000 and it was acquired in 2008 by Pfizer. | $26M / Series D / Jun 28, 2007 | |
BioVigilant Systems
|
BioVigilant Systems invented instantaneous microbial detection technology to address environmental monitoring needs in pharmaceutical, biotechnology, healthcare, and environmental applications. BioVigilant’s IMD systems detect—instantaneously and in real time—particulate count, size, and biological status. Unlike other rapid microbialmethods, BioVigilant’s optically-based systems require no staining, no reagents, no waiting period, and little human intervention. | $6.7M / Series A / May 23, 2006 | |
|
CoLucid Pharmaceuticals
|
CoLucid Pharmaceuticals, Inc., a biotechnology company, focuses on therapies for central nervous system disorders. The company develops COL-144, a neurally acting anti-migraine agent, which is designed to treat migraine; and COL-204, a conjugated stigmine platform that produces novel chemical entities for therapy of sleep/wake disorders,chronic pain, Alzheimer's disease, and psychiatric disorders. CoLucid Pharmaceuticals was founded in 2005 and is based in Research Triangle Park, North Carolina. | $16.5M / Series A / Jan 17, 2006 |
Co-Investors
Domain Associates
4 deals together
Triathlon Medical Venture Partners
4 deals together
Pappas Ventures
2 deals together
Accelerate New York Seed Fund
1 deal together
Auriga Partners
1 deal together
Battelle Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Pearl Street Venture Funds invest in?
Pearl Street Venture Funds invests primarily in Biotechnology, Medical and Robotics startups, most often at Series A and Pre-Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Pearl Street Venture Funds?
Public channels for Pearl Street Venture Funds include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pearl Street Venture Funds?
The team at Pearl Street Venture Funds includes Tim Tichenor (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
